Literature DB >> 23839685

Effects ofL-arginine andN-nitro-L-arginine treatment on hemodynamics, DO2, VO 2, and extravascular lung water in a dog endotoxin shock model.

X Wu1, S Zhang, G Shan.   

Abstract

To verify the effect of nitric oxide pathway modification during sepsis, experiments were conducted in four groups of anesthetized dogs which received lipopolysaccharide (LPS) intravenously (group 1), 300 mg·kg(-1) ofL-arginine plus LPS (group 2), 20 mg·kg(-1) ofN-nitro-L-arginine plus LPS (L-NNA, group 3), and normal saline as the control group. Hemodynamic and oxygenation data as well as extravascular lung water (EVLW) were measured or calculated. The results showed thatL-arginine increases cardiac output index (CI) and decreased the peripheral vascular resistance index (PVRI) without a significant influence on oxygen extraction ratio (O2ER), oxygen delivery (DO2), or oxygen consumption (VO2). All of the untoward hemodynamic effects of LPS were exacerbated by the addition ofL-NNA. Therefore, as DO2 was significantlys decreased byL-NNA, and although O2ER was increased (insufficiently), VO2 was still decreased significantly. EVLW was markedly increased byL-NNA. These results support the hypothesis that inhibition of nitric oxide synthesis may exacerbate hemodynamic and oxygenation consequences in septic shock.

Entities:  

Year:  1997        PMID: 23839685     DOI: 10.1007/BF02480075

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  23 in total

1.  Distribution volumes of [131I]albumin, [14C]sucrose, and 36Cl in sheep lung.

Authors:  S L Selinger; R D Bland; R H Demling; N C Staub
Journal:  J Appl Physiol       Date:  1975-11       Impact factor: 3.531

2.  Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor.

Authors:  S L Archer; J P Tolins; L Raij; E K Weir
Journal:  Biochem Biophys Res Commun       Date:  1989-11-15       Impact factor: 3.575

3.  Effects of inhibition of nitric oxide formation on basal vasomotion and endothelium-dependent responses of the coronary arteries in awake dogs.

Authors:  A Chu; D E Chambers; C C Lin; W D Kuehl; R M Palmer; S Moncada; F R Cobb
Journal:  J Clin Invest       Date:  1991-06       Impact factor: 14.808

4.  Differences in cytokine response and induction of nitric oxide synthase in endotoxin-resistant and endotoxin-sensitive mice after intravenous gram-negative infection.

Authors:  T J Evans; E Strivens; A Carpenter; J Cohen
Journal:  J Immunol       Date:  1993-06-01       Impact factor: 5.422

5.  Role of nitric oxide in the hemodynamic changes of sepsis.

Authors:  J A Lorente; L Landín; E Renes; R De Pablo; P Jorge; E Ródena; D Liste
Journal:  Crit Care Med       Date:  1993-05       Impact factor: 7.598

6.  Effects of inhibition of endothelium-derived relaxation factor on hemodynamics and oxygen utilization during group B streptococcal sepsis in piglets.

Authors:  W Meadow; B Rudinsky; A Bell; R Hipps
Journal:  Crit Care Med       Date:  1995-04       Impact factor: 7.598

7.  NG-methyl-L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide.

Authors:  R G Kilbourn; S S Gross; A Jubran; J Adams; O W Griffith; R Levi; R F Lodato
Journal:  Proc Natl Acad Sci U S A       Date:  1990-05       Impact factor: 11.205

8.  Inhibition of nitric oxide synthesis improves survival in a murine peritonitis model of sepsis that is not cured by antibiotics alone.

Authors:  D M Teale; A M Atkinson
Journal:  J Antimicrob Chemother       Date:  1992-12       Impact factor: 5.790

9.  Induction of nitric oxide synthase activity by toxic shock syndrome toxin 1 in a macrophage-monocyte cell line.

Authors:  A Zembowicz; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

10.  Endothelium-derived relaxing factor inhibits hypoxic pulmonary vasoconstriction in rats.

Authors:  S F Liu; D E Crawley; P J Barnes; T W Evans
Journal:  Am Rev Respir Dis       Date:  1991-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.